ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meeting Abstracts
    • All Meetings
    • ACR Convergence 2026
    • PRSYM 2026
    • ACR Convergence 2025
    • Download Abstract Supplements
  • Keyword Index
  • My Favorites
    • View & print my favorites
  • Search

Abstracts tagged "Ustekinumab and enthesopathy"

  • Abstract Number: 1669 • ACR/ARHP Annual Meeting 2016

    Type 3 Innate Lymphoid Cells Numbers in Peripheral Blood Predict Ustekinumab (Stelara) Therapy Responsiveness in Psoriatic Disease Cases with Subclinical Imaging Enthesopathy

    Yasser El-Sherbiny1, Laura Savage2, Miriam Wittmann3, Mark J. D. Goodfield4 and Dennis McGonagle1, 1Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, 2NIHR Musculoskeletal Biomedical Research Unit, University of Leeds, Leeds, United Kingdom, 3NIHR Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom, 4Dermatology, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom

    Background/Purpose: Ustekinumab1 targets the common p40 sub-unit of interleukin-12 (IL-12/interleukin-23 (IL-23). In patients treated with Ustekinumab for psoriasis where patients were selected on the basis of…

My Favorites

Save and print abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract (must have cookies enabled in browser). See saved favorites.

Abstract Policies

  • ACR Convergence Abstract Embargo Policies
  • ACR Convergence Abstract Permissions & Reprints
  • PRSYM Abstract Policies

ACR Convergence. Where Rheumatology Meets

ACR Convergence 2026

Join us November 6-11 in Orlando, Florida.
See Registration Information

  • Contact ACR
  • Privacy Policy
  • ACR Policies
  • Cookie Preferences

© Copyright 2026 American College of Rheumatology